Date published: 2026-6-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

GTAM5 Marker Antibody (B43.5): sc-59194

2.0(1)
Write a reviewAsk a question

Datasheets
  • GTAM5 Marker Antibody (B43.5) is a mouse monoclonal IgG1 provided at 500 µl supernatant
  • raised against GTAM5 of human origin
  • recommended for detection of GTAM5 of human origin by WB, IF and IHC(P)
  • At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for GTAM5 Marker Antibody (B43.5). This work is in progress.
    Gene Editing Promo Banner

    QUICK LINKS

    SEE ALSO...

    GTAM5 Marker Antibody (B43.5) is a mouse monoclonal IgG1 antibody that detects GTAM5 of human origin by western blotting (WB), immunofluorescence (IF), and immunohistochemistry. Anti-GTAM5 antibody (B43.5) is available as the non-conjugated form. GTAM5, or gastrointestinal tumor associated marker 5, plays a crucial role in identifying gastric carcinoma, a type of cancer that can arise in any part of the stomach and has the potential to metastasize to other organs, including the esophagus and small intestine. GTAM5 is particularly significant as expressed in the luminal and apical cytoplasm of various cancer cells, including those from pancreatic, lung, colon, and gastric carcinomas. GTAM5 is not only a marker of malignancy but also serves as a potential target for therapeutic interventions, making GTAM5 vital for early diagnosis and treatment strategies. The unique expression pattern of GTAM5 in tumor tissues highlights GTAM5′s importance in distinguishing between benign and malignant conditions, thereby aiding in the development of more effective cancer management approaches.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.

    Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA

    LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences

    GTAM5 Marker Antibody (B43.5) References:

    1. Sialosyl-Tn antigen. Its distribution in normal human tissues and expression in adenocarcinomas.  |  Yonezawa, S., et al. 1992. Am J Clin Pathol. 98: 167-74. PMID: 1510031
    2. Characterization of new pancreatic cancer-reactive monoclonal antibodies directed against purified mucin.  |  Ho, JJ., et al. 1991. Cancer Res. 51: 372-80. PMID: 1703039
    3. Relationship of pancreatic cancer apomucin to mammary and intestinal apomucins.  |  Byrd, JC., et al. 1991. Cancer Res. 51: 1026-33. PMID: 1988113
    4. Cancer-associated alterations of blood group antigen expression in the human pancreas.  |  Itzkowitz, SH., et al. 1987. J Natl Cancer Inst. 79: 425-34. PMID: 2442445
    5. Monoclonal antibodies against human milk-fat globule membranes detecting differentiation antigens of the mammary gland and its tumors.  |  Hilkens, J., et al. 1984. Int J Cancer. 34: 197-206. PMID: 6206003
    6. Monoclonal antibody directed against colon cancer mucin has high specificity for malignancy.  |  Siddiki, B., et al. 1993. Int J Cancer. 54: 467-74. PMID: 7685327
    7. Immunohistochemical study of mucin carbohydrates and core proteins in human pancreatic tumors.  |  Osako, M., et al. 1993. Cancer. 71: 2191-9. PMID: 8384065

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    GTAM5 Marker Antibody (B43.5)

    sc-59194
    500 µl supernatant
    $322.00